CCO Infectious Disease Podcast

Key Decisions in HIV Care: Managing ART With Opportunistic Infections

Episode Summary

In this on-demand recording of a live webinar, expert faculty review key considerations for the use of ART in the setting of opportunistic infections. Topics include current data and recommendations for patients with pneumocystis pneumonia, Kaposi sarcoma, cytomegalovirus, and cryptococcal meningitis.

Episode Notes

In this episode from the series “Key Decisions in HIV Care,” Cristina Mussini, MD, and William R. Short, MD, MPH, AAHIVS, discuss important considerations for ART with opportunistic infections, including: 

• When to start ART with pneumocystis pneumonia including discussion of the ACTG 5164 study of immediate vs delayed ART with opportunistic infections
• EACS, DHHS, and IAS-USA guideline recommendations for starting ART in the setting of most opportunistic infections
• Considerations for the administration of ART to patients who are unable to swallow or critically ill and intubated
• Treatment of Kaposi sarcoma and considerations for starting ART to avoid drug–drug interactions with Kaposi sarcoma treatment
• Considerations for starting ART with cytomegalovirus and the risk for IRIS from cytomegalovirus
• Discussion of treatment of cytomegalovirus and overlapping toxicities between its treatment and ART
• When to start ART with cryptococcal meningitis and the data to support delayed treatment initiation with this particular opportunistic infection
• EACS, DHHS, and IAS-USA guideline recommendations for starting ART in the setting of cryptococcal meningitis specifically
• Treatment of cryptococcal meningitis and managing drug–drug interactions between ART and antifungal therapy

Presenters:
Cristina Mussini, MD
Head of Department of Infectious Diseases and Tropical Medicine
Full Professor of Infectious Diseases
Infectious Diseases Clinics 
University Hospital
University of Modena and Reggio Emilia
Reggio Emilia, Italy 

William R. Short, MD, MPH, AAHIVS
Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania 

Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.

Follow along with the slides at:
https://bit.ly/3uktrm1

Link to full program:
https://bit.ly/3q2DlGd